21.09

2.73% -0.9147

Greenwich Lifesciences Inc (GLSI)

Overview News Price History Financials Discussions Forecast

Greenwich Lifesciences Inc stock is traded at $21.09, with a volume of 130.13K. It is down -2.73% in the last 24 hours and down -3.82% over the past month. Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers.

Previous Close:

$22.00

Open:

$22.28

24h Volume:

130.13K

Relative Volume:

0.92

Market Cap:

$310.59M

Revenue:

Net Income/Loss:

$-19.48M

P/E Ratio:

-14.40

EPS:

-1.4641

Net Cash Flow:

$-8.59M

1W Performance:

-7.96%

1M Performance:

-3.82%

6M Performance:

+4.24%

1Y Performance:

+113.36%

1-Day Range:

$20.60

$22.28

1-Week Range:

$20.60

$24.60

52-Week Range:

$7.78

$34.10

Greenwich Lifesciences Inc Stock (GLSI) Company Profile

Name

Greenwich Lifesciences Inc

Sector

Healthcare (1097)

Industry

Biotechnology (615)

Phone

203-434-3290

Address

3992 BLUEBONNET DR, BUILDING 14, STAFFORD

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

GLSI's Discussions on Twitter

Compare GLSI vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GLSI Greenwich Lifesciences Inc	21.16	344.35M	0	-19.48M	-8.59M	-1.4641
VRTX Vertex Pharmaceuticals Inc	527.99	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	647.45	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	926.19	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.63	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.17	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-20-25	Initiated	Noble Capital Markets	Outperform
Sep-01-21	Initiated	H.C. Wainwright	Buy

Greenwich Lifesciences Inc Stock (GLSI) Latest News

Jun 27, 2026

Price to book forward of Greenwich LifeSciences, Inc. – NASDAQ:GLSI - TradingView

Jun 27, 2026

Jun 26, 2026

Precision Trading with Greenwich Lifesciences Inc. (GLSI) Risk Zones - Stock Traders Daily

Jun 26, 2026

Greenwich LifeSciences, Inc. Actuals & Estimates (NASDAQ:GLSI) - TradingView

Jun 26, 2026

Jun 25, 2026

GLSI Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Enterprise value to EBIT forward of Greenwich LifeSciences, Inc. – NASDAQ:GLSI - TradingView

Jun 25, 2026

Price to sales forward of Greenwich LifeSciences, Inc. – NASDAQ:GLSI - TradingView

Jun 25, 2026

Price to earnings forward of Greenwich LifeSciences, Inc. – NASDAQ:GLSI - TradingView

Jun 25, 2026